Entrada Therapeutics (TRDA) Shares Outstanding (2020 - 2026)

Entrada Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 2.29% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $38.8 million (up 2.29% YoY), while the FY2025 annual figure was $38.3 million, up 1.86% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $38.8 million, up from $38.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $38.8 million in Q1 2026, with the low at $31.3 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $33.6 million (2024), against an average of $35.0 million.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) soared 2358.97% in 2022, then climbed 1.35% in 2024.
• Entrada Therapeutics' Shares Outstanding (Entity) stood at $31.4 million in 2022, then climbed by 6.4% to $33.5 million in 2023, then increased by 12.33% to $37.6 million in 2024, then advanced by 1.86% to $38.3 million in 2025, then climbed by 1.4% to $38.8 million in 2026.
• Business Quant data shows TRDA's Shares Outstanding (Entity) at $38.8 million in Q1 2026, $38.3 million in Q4 2025, and $38.2 million in Q3 2025.